The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine

[1]  K. Brøsen,et al.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. , 1989, British journal of clinical pharmacology.

[2]  C. Alm,et al.  S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin , 1989, Clinical pharmacology and therapeutics.

[3]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.

[4]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[5]  S. Preskorn.  Therapeutic drug monitoring of tricyclic antidepressants: a means of avoiding toxicity. , 1989, Psychopharmacology series.

[6]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[7]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[8]  S. Otton,et al.  Sparteine oxidation polymorphism in Denmark. , 2009, Acta pharmacologica et toxicologica.

[9]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[10]  R. Branch,et al.  Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[11]  W. Kalow,et al.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.

[12]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[13]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[14]  L. Bertilsson,et al.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. , 1983, British journal of clinical pharmacology.

[15]  Imipramine metabolites in blood of patients during therapy and after overdose , 1983, Clinical pharmacology and therapeutics.

[16]  S. Bryson.  Clinical Pharmacokinetics: Concepts and applications. , 1983 .

[17]  L. Bertilsson,et al.  Interindividual differences in amitriptyline demethylation , 1980, Clinical pharmacology and therapeutics.

[18]  P. McNamara,et al.  Food, splanchnic blood flow, and bioavailability of drugs subject to first‐pass metabolism , 1978, Clinical pharmacology and therapeutics.

[19]  J. Fleiss,et al.  Clinical implications of imipramine plasma levels for depressive illness. , 1977, Archives of general psychiatry.

[20]  Á. Nagy,et al.  Intestinal absorption, demethylation, and enterohepatic circulation of imipramine , 1976, Clinical pharmacology and therapeutics.

[21]  L. Gram,et al.  First‐pass metabolism of imipramine in man , 1975, Clinical pharmacology and therapeutics.